Dr Reddy's LaboratoriesFRA:RDDA +3.33%91 FCF Margin % is 6.42% as of Mar. 2026, which is 8% above its 10-year median of 5.96. GuruFocus rates FRA:RDDA with a GF Score™ of 91/100 and a GF Value™ of €13.16 (Fairly Valued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Dr Reddy's Laboratories ranks better than 57.93% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories (FRA:RDDA) has a FCF Margin % of 6.42% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dr Reddy's Laboratories and its competitors. This is near median its historical median of 5.96. According to the industry distribution chart, Dr Reddy's Laboratories ranks #403 out of 958 companies in the Drug Manufacturers industry, placing it in the top 42.1%.
Is Dr Reddy's Laboratories' FCF Margin % too high?
Dr Reddy's Laboratories' current FCF Margin % of 6.42% is near median its 10-year median of 5.96. The Drug Manufacturers industry median FCF Margin % is 2.51. Dr Reddy's Laboratories' value of 6.42% is 155.8% above this industry median. Based on the distribution chart, Dr Reddy's Laboratories ranks #403 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dr Reddy's Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dr Reddy's Laboratories ranks #403 out of 958 companies for FCF Margin %. This puts Dr Reddy's Laboratories in the upper half of its industry. The industry median FCF Margin % is 2.51. Dr Reddy's Laboratories' value of 6.42% is 155.8% above this benchmark. While the company's 10-year median is 5.96 vs. the industry median of 2.51, Dr Reddy's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Reddy's Laboratories's current FCF Margin % of 6.42% is 155.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dr Reddy's Laboratories and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Reddy's Laboratories's current FCF Margin % is 6.42%, which is near median its own 10-year median of 5.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Fairly Valued. The stock's GF Value™ is €13.16, compared to a current price of €12.40 — trading 5.8% below its estimated fair value. The current FCF Margin % is 6.42%, which is near median its 10-year median of 5.96 and 155.8% above the Drug Manufacturers industry median of 2.51. Dr Reddy's Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current FCF Margin % is 6.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of €12.40 is trading 5.8% below its estimated GF Value™ of €13.16.
GuruFocus considers Dr Reddy's Laboratories to be Fairly Valued.
Key valuation signals for FRA:RDDA:
FCF Margin %: 6.42% (near median its 10-year median of 5.96)
GF Value™: €13.16 vs. price of €12.40 (5.8% below fair value)
Industry Position: 155.8% above the Drug Manufacturers median (#403 of 958)
No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
91GF Score
Get the complete analysis for FRA:RDDA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RDDA has been successfully added to your 
